- Home
- NRXS vs IMA Comparison
NRXS vs IMA Comparison
Compare NRXS & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRXS | IMA |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.0M | 66.3M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NRXS | IMA |
|---|---|---|
| Price | $7.62 | $4.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $11.00 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 133.4K | 12.1K |
| Earning Date | 11-09-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.13 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,569,282.00 | $800,000.00 |
| Revenue This Year | $132.54 | N/A |
| Revenue Next Year | $138.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.89 | N/A |
| 52 Week Low | $2.21 | $3.88 |
| 52 Week High | $9.33 | $8.84 |
Technical Indicators
Market Signals| Indicator | NRXS | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 55.98 | 37.84 |
| Support Level | $6.36 | $3.92 |
| Resistance Level | $7.79 | $6.13 |
| Average True Range (ATR) | 0.43 | 0.22 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 75.61 | 29.83 |
Price Performance
Historical ComparisonAbout NRXS Neuraxis Inc.
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.